Oxford BioDynamics Plc receives €4 million Horizon 2020 award

Oxford BioDynamics Plc (LONOBD) today announced that it has been chosen as an industrial partner in a Horizon 2020 international research and innovation collaboration. The initiative on “Predictive Epigenetics” (PEP-NET), which has been granted €4 million, brings together an international consortium of 11 leading epigenetic research centres and five partner organisations* to develop practical translation of epigenetic regulation into therapeutically actionable outcomes.

The PEP-NET consortium comprises experimentalists and theoreticians whose goal is to develop a joint predictive modelling framework to further the understanding of fundamental epigenetic mechanisms. The outcome will present real world applications for the development of new technologies, and diagnostic and therapeutic tools to benefit patients.

This will be an important opportunity for OBD to increase utilisation of its EpiSwitch™ platform and further develop its technology globally, while helping to improve understanding of epigenetic controls and mechanisms. As an industry partner in this initiative, all parties will have access to OBD’s intellectual property for research purposes only.

Consortium member Professor Leonie Ringrose, Institute of Biology, Humboldt University, Berlin, commented:

“Epigenetic mechanisms are profoundly implicated in human health and disease. Despite the availability of large amounts of molecular data sets today, the field is still far from a satisfactory mechanistic understanding of many epigenetic processes. This unique collaboration of frontline researchers and commercial companies aims to combine quantitative experiments, predictive theoretical models, new modeling of data analysis and latest industrial tools of detection and monitoring to understand epigenetic regulation, with the aim to achieve both deeper fundamental understanding and better practical translation of epigenetic regulation into actionable patient stratifications. We have seen the practical value of EpiSwitch™ and believe this powerful platform will allow us to develop real world solutions.

PEP-NET will train a generation of European researchers to combine quantitative experiments with predictive theoretical models, and will exploit this knowledge to answer both basic and applied questions in epigenetics.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,